Abhijeet Kumar
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Abhijeet Kumar has a total of 74 co-authors. Here are the top co-authors by number of shared publications:
Pulkit Saini
Sri Devaraj Urs Medical College, Kolar, Karnataka, India
2 shared publications- Rafael Everton Assunção Ribeiro da Costa
State University of Campinas (UNICAMP), Cidade Universitária “Zeferino Vaz”, Campinas, São Paulo, Brazil
2 shared publications Shreya Singh Beniwal
Lady Hardinge Medical College, Connaught Place, New Delhi, India
2 shared publications- Abdullah1 shared publication
- Abhijeet Chatterjee1 shared publication
- Ajay V. Kaduskar1 shared publication
Latest Publications
- Open Access
- 18 September 2026
- Published by Elsevier in The Lancet Regional Health - Southeast Asia
The Varanasi Declaration 2026: an India-specific consensus policy framework for integrated cardiovascular–kidney–metabolic care
- 18 September 2026
- Published by Elsevier in The Lancet Regional Health - Southeast Asia
Open AccessThe Varanasi Declaration 2026: an India-specific consensus policy framework for integrated cardiovascular–kidney–metabolic care
- 1 May 2026
- Published by SAGE Publications in Human Antibodies
- Vol. 34 (1-2) , 11-18
Association between iron deficiency Anemia and allergic conditions: A retrospective analysis
Background: Iron deficiency anemia (IDA) is a prevalent nutritional deficiency linked to immune modulation and allergic conditions. This study investigates the association between IDA and allergic diseases, including atopic dermatitis, asthma, allergic rhinitis, food allergy, and allergic eosinophilia. Objective: To evaluate the association between iron deficiency anemia (IDA) and the prevalence of allergic conditions, including atopic dermatitis, asthma, allergic rhinitis, food allergy, and allergic eosinophilia, using a large nationally representative dataset. Methods: A retrospective, cross-sectional design was employed using data from the National Inpatient Sample (2016–2020). Logistic regression models adjusted for confounders such as payer type, race, socioeconomic status, and hospital characteristics were used to assess associations. Results: Among 32,966,720 patients, 1,247,309 (3.8%) had IDA. After adjustment, IDA was significantly associated with increased odds of allergic conditions: atopic dermatitis (OR = 1.30), asthma (OR = 1.21), allergic rhinitis (OR = 1.21), food allergy (OR = 1.18), and allergic eosinophilia (OR = 1.24). Conclusion: IDA was significantly associated with allergic conditions in this analysis, suggesting that iron status may represent a clinically relevant factor in patients with allergic diseases, as seen in this large national inpatient sample. Future longitudinal studies are needed to clarify causal pathways and develop targeted interventions. Addressing nutritional deficiencies may reduce the burden of allergic diseases and improve health outcomes.
- 1 May 2026
- Published by SAGE Publications in Human Antibodies
- Vol. 34 (1-2) , 11-18
Association between iron deficiency Anemia and allergic conditions: A retrospective analysis
Background: Iron deficiency anemia (IDA) is a prevalent nutritional deficiency linked to immune modulation and allergic conditions. This study investigates the association between IDA and allergic diseases, including atopic dermatitis, asthma, allergic rhinitis, food allergy, and allergic eosinophilia. Objective: To evaluate the association between iron deficiency anemia (IDA) and the prevalence of allergic conditions, including atopic dermatitis, asthma, allergic rhinitis, food allergy, and allergic eosinophilia, using a large nationally representative dataset. Methods: A retrospective, cross-sectional design was employed using data from the National Inpatient Sample (2016–2020). Logistic regression models adjusted for confounders such as payer type, race, socioeconomic status, and hospital characteristics were used to assess associations. Results: Among 32,966,720 patients, 1,247,309 (3.8%) had IDA. After adjustment, IDA was significantly associated with increased odds of allergic conditions: atopic dermatitis (OR = 1.30), asthma (OR = 1.21), allergic rhinitis (OR = 1.21), food allergy (OR = 1.18), and allergic eosinophilia (OR = 1.24). Conclusion: IDA was significantly associated with allergic conditions in this analysis, suggesting that iron status may represent a clinically relevant factor in patients with allergic diseases, as seen in this large national inpatient sample. Future longitudinal studies are needed to clarify causal pathways and develop targeted interventions. Addressing nutritional deficiencies may reduce the burden of allergic diseases and improve health outcomes.
- Open Access
- 17 December 2025
- Published by Wiley in Endocrinology, Diabetes & Metabolism
- Vol. 9 (1) , e70149
Circular RNAs as Biomarkers and Therapeutic Targets in Diabetic Cardiovascular Complications
Background: The global prevalence of diabetes mellitus (DM) is rising rapidly and is projected to reach unprecedented levels by 2035 and 2050, with a disproportionate burden among elderly populations and in low‐ and middle‐income countries. Diabetes‐related cardiovascular complications remain a leading cause of morbidity and mortality despite advances in glycaemic control and pharmacotherapy. There is an urgent need for novel molecular biomarkers and therapeutic targets to improve early detection, risk stratification, and personalised management. Methods: A comprehensive narrative review of the current literature was conducted to summarise emerging evidence on the biological roles of circular RNAs (circRNAs) in diabetes and its cardiovascular complications. Published experimental, translational, and clinical studies investigating circRNA expression, mechanisms of action, and therapeutic potential were critically analysed. Results: CircRNAs have emerged as key regulators in the pathophysiology of diabetes‐associated cardiovascular disorders, including diabetic cardiomyopathy, endothelial dysfunction, and vascular inflammation, as well as related microvascular complications. Mechanistically, circRNAs act through diverse pathways such as microRNA sponging, modulation of gene transcription, interaction with RNA‐binding proteins, and regulation of cellular processes including apoptosis, fibrosis, oxidative stress, and inflammation. Their covalently closed structure confers exceptional stability, while their tissue‐ and disease‐specific expression profiles support their utility as sensitive biomarkers for early diagnosis, prognosis, and therapeutic monitoring. Advances in synthetic circRNA design further highlight their promise as novel therapeutic agents, although challenges related to delivery efficiency, specificity, and off‐target effects remain. Conclusions: CircRNAs represent a promising class of biomarkers and therapeutic targets in diabetes‐related cardiovascular complications. Their stability, specificity, and functional versatility position them as attractive tools for precision medicine approaches in diabetes care. Further mechanistic studies and well‐designed clinical investigations are essential to translate circRNA‐based diagnostics and therapeutics into clinical practice.
- 17 December 2025
- Published by Wiley in Endocrinology, Diabetes & Metabolism
- Vol. 9 (1) , e70149
Open AccessCircular RNAs as Biomarkers and Therapeutic Targets in Diabetic Cardiovascular Complications
Background: The global prevalence of diabetes mellitus (DM) is rising rapidly and is projected to reach unprecedented levels by 2035 and 2050, with a disproportionate burden among elderly populations and in low‐ and middle‐income countries. Diabetes‐related cardiovascular complications remain a leading cause of morbidity and mortality despite advances in glycaemic control and pharmacotherapy. There is an urgent need for novel molecular biomarkers and therapeutic targets to improve early detection, risk stratification, and personalised management. Methods: A comprehensive narrative review of the current literature was conducted to summarise emerging evidence on the biological roles of circular RNAs (circRNAs) in diabetes and its cardiovascular complications. Published experimental, translational, and clinical studies investigating circRNA expression, mechanisms of action, and therapeutic potential were critically analysed. Results: CircRNAs have emerged as key regulators in the pathophysiology of diabetes‐associated cardiovascular disorders, including diabetic cardiomyopathy, endothelial dysfunction, and vascular inflammation, as well as related microvascular complications. Mechanistically, circRNAs act through diverse pathways such as microRNA sponging, modulation of gene transcription, interaction with RNA‐binding proteins, and regulation of cellular processes including apoptosis, fibrosis, oxidative stress, and inflammation. Their covalently closed structure confers exceptional stability, while their tissue‐ and disease‐specific expression profiles support their utility as sensitive biomarkers for early diagnosis, prognosis, and therapeutic monitoring. Advances in synthetic circRNA design further highlight their promise as novel therapeutic agents, although challenges related to delivery efficiency, specificity, and off‐target effects remain. Conclusions: CircRNAs represent a promising class of biomarkers and therapeutic targets in diabetes‐related cardiovascular complications. Their stability, specificity, and functional versatility position them as attractive tools for precision medicine approaches in diabetes care. Further mechanistic studies and well‐designed clinical investigations are essential to translate circRNA‐based diagnostics and therapeutics into clinical practice.